Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis Mulleman

Showing results (1-10 of 98) with videos related to

Pageof 10
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|January 29, 2014
Do immunoglobulin levels and CD4 cell count interact during Rituximab treatment?Denis Mulleman
The New England Journal of Medicine|January 27, 2006
Medical mystery: extensive ecchymosis--the answerDenis Mulleman, Philippe Goupille
The New England Journal of Medicine|December 2, 2005
Images in clinical medicine. A medical mystery--extensive ecchymosisDenis Mulleman, Philippe Goupille
Annals of the Rheumatic Diseases|January 8, 2018
Adalimumab concentration-based tapering strategy: as good as the recommended dosageDenis Mulleman, Alejandro Balsa
Medecine Sciences : M/S|January 7, 2020
[Rheumatology, the multitude of options]Jacques Morel, Denis Mulleman
The Journal of Rheumatology|July 1, 2026
Rethinking Anti-CD20 Therapies: From Fixed to Precision DosingDenis Mulleman, Katarina Vučićević, James Bluett
Arthritis Research & Therapy|December 19, 2007
Is interleukin-1 a good target for therapeutic intervention in intervertebral disc degeneration: lessons from the osteoarthritic experiencePhilippe Goupille, Denis Mulleman, Xavier Chevalier
Trends in Biotechnology|May 6, 2026
Detection of anti-drug antibodies during monoclonal antibody drug therapyFrans Kokojka, Denis Mulleman, Robert S Marks
Joint Bone Spine|May 27, 2026
Novel Tools for Targeted Therapies in Difficult-to-Treat Rheumatic DiseasesAndrea Rolong, Guillermo Carvajal Alegria, Denis Mulleman
Joint Bone Spine|April 5, 2011
Optimizing TNFα antagonist therapy in patients with spondyloarthritis: why and how?Daniel Wendling, Clément Prati, Philippe Goupille, et al.
Pageof 10

Showing results (1-10 of 98) with videos related to

Sort By:
Pageof 10
Arthritis & Rheumatology (Hoboken, N.J.)|January 29, 2014
Do immunoglobulin levels and CD4 cell count interact during Rituximab treatment?Denis Mulleman
The New England Journal of Medicine|January 27, 2006
Medical mystery: extensive ecchymosis--the answerDenis Mulleman, Philippe Goupille
The New England Journal of Medicine|December 2, 2005
Images in clinical medicine. A medical mystery--extensive ecchymosisDenis Mulleman, Philippe Goupille
Annals of the Rheumatic Diseases|January 8, 2018
Adalimumab concentration-based tapering strategy: as good as the recommended dosageDenis Mulleman, Alejandro Balsa
Medecine Sciences : M/S|January 7, 2020
[Rheumatology, the multitude of options]Jacques Morel, Denis Mulleman
The Journal of Rheumatology|July 1, 2026
Rethinking Anti-CD20 Therapies: From Fixed to Precision DosingDenis Mulleman, Katarina Vučićević, James Bluett
Arthritis Research & Therapy|December 19, 2007
Is interleukin-1 a good target for therapeutic intervention in intervertebral disc degeneration: lessons from the osteoarthritic experiencePhilippe Goupille, Denis Mulleman, Xavier Chevalier
Trends in Biotechnology|May 6, 2026
Detection of anti-drug antibodies during monoclonal antibody drug therapyFrans Kokojka, Denis Mulleman, Robert S Marks
Joint Bone Spine|May 27, 2026
Novel Tools for Targeted Therapies in Difficult-to-Treat Rheumatic DiseasesAndrea Rolong, Guillermo Carvajal Alegria, Denis Mulleman
Joint Bone Spine|April 5, 2011
Optimizing TNFα antagonist therapy in patients with spondyloarthritis: why and how?Daniel Wendling, Clément Prati, Philippe Goupille, et al.
Pageof 10